Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12314
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAndrews, Miles Cen
dc.contributor.authorWoods, Katherineen
dc.contributor.authorCebon, Jonathan Sen
dc.contributor.authorBehren, Andreasen
dc.date.accessioned2015-05-16T01:58:43Z-
dc.date.available2015-05-16T01:58:43Z-
dc.date.issued2014-06-01en
dc.identifier.citationFuture Oncology (london, England); 10(8): 1457-68en
dc.identifier.govdoc25052755en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12314en
dc.description.abstractHuman tumor rejection antigens recognized by T lymphocytes were first defined in the early 1990s and the identification of shared tumor-restricted antigens sparked hopes for the development of a therapeutic vaccination to treat cancer, including melanoma. Despite decades of intense preclinical and clinical research, the success of anticancer vaccines based on these antigens has been limited. While melanoma is a highly immunogenic tumor, the ability to prime immunity with vaccines has not generally translated into objective disease regression. However, with the development of small molecules targeting oncogenic proteins, such as V600-mutated BRAF, and immune checkpoint inhibitors with demonstrable long-lasting clinical benefit, new opportunities for antigen-targeted directed therapies are emerging.en
dc.language.isoenen
dc.subject.othercheckpoint inhibitorsen
dc.subject.othercombination treatmentsen
dc.subject.otherimmunotherapyen
dc.subject.otherMelanomaen
dc.subject.othertumor antigensen
dc.subject.otherAdaptive Immunityen
dc.subject.otherAntigens, Neoplasm.immunology.metabolismen
dc.subject.otherCancer Vaccinesen
dc.subject.otherHumansen
dc.subject.otherImmunomodulationen
dc.subject.otherImmunotherapy, Adoptiveen
dc.subject.otherMelanoma.immunology.metabolism.therapyen
dc.subject.otherTumor Escape.immunologyen
dc.titleEvolving role of tumor antigens for future melanoma therapies.en
dc.typeJournal Articleen
dc.identifier.journaltitleFuture oncology (London, England)en
dc.identifier.affiliationLudwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.2217/fon.14.84en
dc.description.pages1457-68en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25052755en
dc.type.austinJournal Articleen
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Feb 3, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.